Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.uniQure has entered into partnership with Chiesi Farmaceutici to commercialize Glybera, the first gene therapy to receive regulatory approval in Europe, and to co-develop a gene therapy for hemophilia B.
Subscribe to our email newsletter
As part of the agreement, uniQure has achieved $21.8m (€17m) in financing agreement as well as $18m (€14m) in equity financing from Chiesi.
It has also converted the previously announced $18.1m (€14.1m) into equity investment which was led by Coller Capital (London, UK) with participation by existing investors.
uniQure gives exclusive rights to Chiesi to commercialize Glybera, for the treatment of the orphan disease lipoprotein lipase deficiency (LPLD) for which there is no treatment, as well as for uniQure’s pipeline product for hemophilia B.
In exchange, uniQure receives net royalties that range from 20% to 30% over time on sales of both the products.
Additionally, Chiesi will fund half of the remaining development costs for uniQure’s hemophilia B program, as well as take an equity stake in uniQure.
uniQure CEO Jörn Aldag said, "In the next 12-18 months, we anticipate clarifying the path toward an FDA filing for Glybera in the US, reporting results from a Phase I/II study in acute intermittent porphyria, and starting at least two Phase I/II studies for additional pipeline programs."